MicroRNAs (miRNAs) are tiny RNA molecules that regulate gene expression by controlling messenger RNAs (mRNAs) and are ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Reprogrammable RNA nanoparticles activate only in cancer cells to deliver targeted gene-silencing therapy while avoiding ...

“Newer RNA interference therapeutics, patisiran and vutrisiran, show significant promise as an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM),” Farhan Naeem, MD, from ...

Sea cucumbers (Apostichopus japonicus) have been slowly disappearing from ocean floors over the last few decades, mostly due ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...